Señales en vivo de SCYX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	173 075
Volumen promedio	204 491
Capitalización de mercado	66.82M
EPS	$-0.390 ( 2024-03-29 )
Próxima fecha de ganancias	( $-0.180 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1.270
ATR14	$0.00800 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Sukenick Scott	Sell	15 179	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	290 590	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	431 030	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	215 515	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	143 675	Common Stock

INSIDER POWER
98.25
Last 93 transactions
Buy: 4 299 100 \| Sell: 614 179

Volumen Correlación

Largo: 0.03 (neutral)

Corto: 0.23 (neutral)

Signal:(50.496) Neutral

SCYNEXIS Inc Correlación

10 Correlaciones Más Positivas
WSBF	0.889
XELA	0.888
ZSAN	0.887
QLGN	0.874
SWVL	0.874
CIVB	0.873
CBAN	0.87
KTTA	0.866
CLBK	0.861
CHMG	0.86

10 Correlaciones Más Negativas
CROX	-0.88
AVAC	-0.874
FNVT	-0.872
GDNR	-0.871
BTWN	-0.87
XENT	-0.869
MLVF	-0.866
ADAL	-0.864
CNGL	-0.863
HWCC	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SCYNEXIS Inc Correlación - Moneda/Commodity

0.54
( weak )

0.46
( neutral )

0.00
( neutral )

0.52
( weak )

0.00
( neutral )

-0.46
( neutral )

SCYNEXIS Inc Finanzas

Annual	2023
Ingresos:	$140.14M
Beneficio Bruto:	$123.71M (88.27 %)
EPS:	$1.400

FY	2023
Ingresos:	$140.14M
Beneficio Bruto:	$123.71M (88.27 %)
EPS:	$1.400

FY	2022
Ingresos:	$5.09M
Beneficio Bruto:	$4.46M (87.66 %)
EPS:	$-1.470

FY	2021
Ingresos:	$13.16M
Beneficio Bruto:	$12.85M (97.63 %)
EPS:	$-1.250

Financial Reports:

No articles found.

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.